Regenicin, Inc.
RGIN
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 799.80K | 722.20K | 601.10K | 558.50K | 561.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 894.50K | 722.20K | 601.10K | 558.50K | 561.40K |
| Operating Income | -894.50K | -722.20K | -601.10K | -558.50K | -561.40K |
| Income Before Tax | -932.40K | -762.60K | -639.20K | -595.90K | -598.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.93 | -0.76 | -0.64 | -0.60 | -0.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -932.40K | -762.60K | -639.20K | -595.90K | -598.10K |
| EBIT | -894.50K | -722.20K | -601.10K | -558.50K | -561.40K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 613.93M | 613.93M | 613.93M | 613.93M | 613.93M |
| Average Diluted Shares Outstanding | 613.93M | 613.93M | 613.93M | 613.93M | 613.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |